Observational studyJournal of gastroenterology2023
Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
Observational study in Journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 15 citations in OpenAlex.
- First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.Journal of gastroenterology · 2025Trial
- Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan.Advances in therapy · 2026Article
- Long-Term Real-World Evaluation of Tofacitinib's Effectiveness and Safety in Japan: Insights Into Optimal Timing for Dose Reduction.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Diagnostic accuracy of endoscopic findings for cytomegalovirus reactivation in hospitalized patients with ulcerative colitis.PloS one · 2026Article
- Severe ulcerative colitis: diagnostic criteria and therapy.Journal of gastroenterology · 2025Article
- Reply to "Severe ulcerative colitis: diagnostic criteria and therapy".Journal of gastroenterology · 2025Article
- Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching.Scientific reports · 2025Article
- What to do when traditional rescue therapies fail in acute severe ulcerative colitis.Intestinal research · 2024Review
- Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management.World journal of gastroenterology · 2024Article
- Efficacy of upadacitinib in the achievement of clinical and endoscopic remission in hospitalized patients with ulcerative colitis.Clinical journal of gastroenterology · 2024Article
- Reply to "promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy".Journal of gastroenterology · 2024Article
- Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy.Journal of gastroenterology · 2024Article
- Treatment endpoints in ulcerative colitis: Does one size fit all?World journal of gastrointestinal pharmacology and therapeutics · 2024Article
- Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.Journal of gastroenterology · 2024Article
- Comparison of Tacrolimus and Infliximab for Acute Severe Ulcerative Colitis in Hospitalized Adults: A Retrospective Study.Journal of digestive diseasesArticle
- Effectiveness of Intravenous Corticosteroid in Patients with Ulcerative Colitis after Oral Corticosteroid Failure: Differences by Prior Response to Oral Therapy in a Multicenter Cohort Study.Inflammatory intestinal diseasesArticle
Corrections and comments
- Commented on by
Authors and funding
25 authors at 20 institutions in 1 country.
Funding
Abstract
backgroundThis multicenter observational cohort study aimed to evaluate the utilization and short-term efficacy of advanced therapy (AT) in hospitalized patients with acute severe ulcerative colitis (ASUC).
methodsIn total, 221 patients with ASUC were enrolled between August 2020 and July 2021. The primary endpoint was clinical remission (CR, defined as a patient-reported outcome score < 2 with no blood in the stool) rate on Day 7 and 14 in hospitalized patients who received corticosteroids (CS) and AT.
resultsAmong patients with ASUC, 120 and 101 patients received CS or any AT as first-line treatment, respectively. The CR rates on Day 7 and 14 were 22.5% and 35.0%, respectively, in hospitalized patients who received CS as first-line treatment. Most patients who used ATs had CS-dependent or frequent recurrences. Eight different ATs (apheresis, tacrolimus, infliximab, golimumab, tofacitinib, vedolizumab, ustekinumab, and cyclosporine) were used as first-line treatment in patients with ASUC, and the CR rates on Day 7 and 14 were 16.8% and 29.7%, respectively. Twenty-five patients received the second ATs after hospitalizations, and the CR rates on Day 7 and 14 were 0% and 12%, respectively. The CR rates on Day 14 were significantly higher in patients who changed to AT than in those whose dose of CS increased (34.0% vs 10.7%, p = 0.020) among patients who had already used CS before hospitalization.
conclusionMost first-use ATs were effective for patients with ASUC, while second-use ATs might have had limited benefits in inducing CR. These findings may contribute to considerations for the management of hospitalized patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.